Dermira Inc. (DERM) Stock Rating Upgraded by Zacks Investment Research
Dermira Inc. (NASDAQ:DERM) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Friday.
According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
A number of other brokerages have also recently issued reports on DERM. Needham & Company LLC reiterated a “positive” rating and issued a $46.00 price target on shares of Dermira in a research note on Monday, October 3rd. Leerink Swann reiterated a “buy” rating on shares of Dermira in a research note on Wednesday, October 5th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $41.00.
Dermira (NASDAQ:DERM) opened at 33.86 on Friday. The stock has a 50 day moving average of $33.06 and a 200-day moving average of $31.69. Dermira has a 52-week low of $17.42 and a 52-week high of $36.34. The company’s market capitalization is $1.21 billion.
Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.72). On average, equities research analysts anticipate that Dermira will post ($3.32) earnings per share for the current fiscal year.
In other Dermira news, CEO Thomas G. Wiggans sold 11,000 shares of the business’s stock in a transaction dated Tuesday, November 1st. The stock was sold at an average price of $31.19, for a total value of $343,090.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Christopher M. Griffith sold 1,303 shares of the business’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $33.26, for a total value of $43,337.78. Following the completion of the transaction, the vice president now directly owns 45,165 shares of the company’s stock, valued at approximately $1,502,187.90. The disclosure for this sale can be found here. 17.30% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. Monashee Investment Management LLC raised its stake in Dermira by 385.1% in the second quarter. Monashee Investment Management LLC now owns 125,965 shares of the biopharmaceutical company’s stock valued at $3,684,000 after buying an additional 100,000 shares during the last quarter. Glenmede Trust Co. NA acquired a new stake in Dermira during the second quarter valued at approximately $170,000. American Century Companies Inc. acquired a new stake in Dermira during the second quarter valued at approximately $1,352,000. BlackRock Advisors LLC raised its stake in Dermira by 29.5% in the second quarter. BlackRock Advisors LLC now owns 420,188 shares of the biopharmaceutical company’s stock valued at $12,291,000 after buying an additional 95,784 shares during the last quarter. Finally, EAM Investors LLC acquired a new stake in Dermira during the second quarter valued at approximately $3,257,000. 83.64% of the stock is owned by hedge funds and other institutional investors.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Stock Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related stocks with our FREE daily email newsletter.